Clinical Scorecard: Characterizing Severe Clostridioides difficile Infections: Evaluating the Role of Hypotension as a Diagnostic Indicator

At a Glance

Key Highlights

• FCDI is associated with a 30%–40% mortality rate and prolonged ICU admission.
• Hypotension defined as systolic blood pressure ≤90 mm Hg or mean arterial pressure ≤65 mm Hg improves prediction of poor outcomes in FCDI.
• Removal of hypotension from severity criteria worsens predictive ability for adverse outcomes such as colectomy or death.

Guideline-Based Recommendations

Diagnosis

• Use 2017 IDSA/SHEA CDI guidelines to classify CDI severity including nonsevere, severe, and fulminant categories.
• Include hypotension defined objectively as SBP ≤90 mm Hg or MAP ≤65 mm Hg in FCDI severity criteria.

Management

• Identify patients with FCDI based on presence of ileus, toxic megacolon, shock, or hypotension for prompt intensive care and treatment.
• Consider vasopressor support in hypotensive patients as part of management.

Monitoring & Follow-up

• Monitor vital signs closely within 24 hours of CDI diagnosis, focusing on lowest SBP, DBP, and MAP values.
• Track vasopressor use within 48 hours following CDI diagnosis.

Risks

• Patients with hypotension (SBP ≤90 mm Hg or MAP ≤65 mm Hg) are at higher risk for colectomy or mortality within 30 days.
• Failure to recognize hypotension as a severity marker may delay appropriate care and worsen outcomes.

Patient & Prescribing Data

Hospitalized adults diagnosed with CDI across multiple US hospital systems

Inclusion of hypotension criteria enhances identification of high-risk patients who may benefit from escalated care including vasopressors.

Clinical Best Practices

• Apply objective hypotension definitions (SBP ≤90 mm Hg or MAP ≤65 mm Hg) when classifying FCDI severity.
• Use composite endpoints of colectomy or CDI-attributable mortality within 30 days to assess severity and outcomes.
• Incorporate hypotension assessment into routine vital sign monitoring for CDI patients.
• Validate severity criteria across diverse patient cohorts to ensure generalizability.

References

• 2017 IDSA/SHEA Clinical Practice Guidelines for Clostridium difficile Infection
• Centers for Disease Control and Prevention National Healthcare Safety Network Multidrug-Resistant Organism/CDI Module